FDA recommends that drug sponsors conduct simulation studies with healthcare professionals to evaluate the safety of a proposed proprietary name for a drug product.
The agency describes how to design such studies in its draft guidance “Best Practices in Developing Proprietary Names for Drugs.” FDA announced the availability of the document in...